{"ticker": {"uuid": "fa26c959-2087-470a-96c3-db662b81c34d", "symbol": "CORT", "name": "Corcept Therapeutics Incorporated", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Corcept Sets July 29 Results Call for 5 p.m. Eastern", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPLXowYnNpR3JoZVZnVEk3SWJwYU8tV1E0bS1ZTU15bUo0RkplakhBYUtSbTczc3c5enF6V1NXWWhlMklqajhfNjB6VmNiRmd6cnBDLWVQUkVsb2d6SWFPQjY1UWV0dkQ2dDRORFo3NDFVZkpqbUd3dzhrd2k0TmZRb1MxbE1Jc1hLZUdpU18xNU1uQ0lRQjdUU0Qya1d1bFFjWDdGQUQtSzJjdzBEZG9ydlkwV0lNdmdJRExHNQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-22T20:11:59+00:00", "published_display": "22 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/corcept-therapeutics-announce-second-quarter-200500598.html", "source_name": "Business Wire", "published_at": "2026-07-22T20:05:00+00:00", "published_display": "22 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics stock hits 52-week high at 95.18 USD By Investing.com", "summary": "Corcept Therapeutics (CORT) stock has climbed to a new 52-week high of $95.18, showcasing a 152% return over the past six months and a 163% year-to-date gain, reflecting strong investor confidence and strategic advancements. Despite an InvestingPro analysis indicating the stock m", "url": "https://ca.investing.com/news/stock-market-news/corcept-therapeutics-stock-hits-52week-high-at-9518-usd-93CH-4744412", "source_name": "Investing.com Canada", "published_at": "2026-07-21T14:09:47", "published_display": "21 Jul 2026 14:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% \u2014 Here's What Investors Should Know", "summary": "", "url": "https://finance.yahoo.com/m/735c6d8c-f879-38f7-aea3-94f59ba12108/corcept%27s-cfo-set-his-selling.html", "source_name": "Motley Fool", "published_at": "2026-07-21T00:38:52+00:00", "published_display": "21 Jul 2026 00:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound", "summary": "", "url": "https://finance.yahoo.com/m/b549078f-abaa-3db0-b092-6229b1275909/a-corcept-director-holds-1.5.html", "source_name": "Motley Fool", "published_at": "2026-07-21T00:28:29+00:00", "published_display": "21 Jul 2026 00:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept stock trades near recent highs as Korlym revenue and margins support growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNQ3RCX1Mwelg1alF1OVRwMzBiS2lTeGF0NmRXaTBBY0UwRHVxeDNGTWxXSFNlZHQzTUIzd0FRRGFaS0NYUUU2a2tYSjgyd1VMVWtQSGUtSzdrUHo3Q0NjamdaSXZubDFjMlNJVUxaSUtYSjN3RG9qeTUwM3cyQ2cyVkxCdEZyVWgyVFZUZlZOZ2RNeHB2YmNnbkxPbmxfQ0FObGVvOXhvTjZnYTZYeDdjUjNFajBKSVN4cGt6YzFnNFBNMFM4TkE?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-20T18:09:26+00:00", "published_display": "20 Jul 2026 18:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trump Disclosure Shows Corcept Buy Before FDA Approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQeDdDZU1hLVgyZVUtRjB2OGJuU0JuY2ZtcFpjdDc4X2NhRENqVHJmc0RLSDlrT1Njd3o3VWl6VGp3RHh0amI2X1h3WXNUeWMtSnZwdV9jbWN1b0RzVXpuWUE5cjhMdERzVi1Vc2VhTHp4b1EzYXlBeGhKdXZsYzRJeWcySXZwa3lYckZCZTBjVm8?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-20T17:37:00+00:00", "published_display": "20 Jul 2026 17:37", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics Insider Sold Shares Worth $3,508,277, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/corcept-therapeutics-insider-sold-shares-075204192.html", "source_name": "MT Newswires", "published_at": "2026-07-20T07:52:04+00:00", "published_display": "20 Jul 2026 07:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics (CORT) Stock Could Trade At A Discount As Its 346% Run Looms", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxPOUN4M3RGb3lLMV9ManppaTJfU3U1SllMZTlkY045M3hVZ0kzeDN5MHIySXh2UkltUExxSzVQaDhJRlRBQWNDYVFvYXVFTjFyamEwTy1JVG84V0Jtajh6MzJ5ZU1UMlotanZLSWVpWG85Q2JOQjNpdV91MVYwRjhXUFRTTHIzS1ZOOEZIZEpncUlVRkpqcDVHYWlOZ3o1dFZ1bzJuRUEwUm1DMkxrU2JfQlpQMU9vT3JPN1dqaEVyMHdPcWZ5Z0w2Y21wN0FMWm9FeG5ZRnZIWVdRemZCV0NEOFNIeDkwaVdtMWfSAe8BQVVfeXFMTnpYVTNqdnJ5TE1EbGhERUtsVmFaT0hVb1FLNUNNRjlMbEpEMkxQZ0ozMEZISlRIQV9ibU1IOGpuSk5sZlJBcFN2WUhVY0p3SjlYNEFIRkdtem9PX3lzTlJhYjc5aGcxZ2NBdzRDWE9CZmtNNWdlOW1tMzRyX2tackxxajR2d0xkUk85Z2ZGelJtSXc4WXRva2FoYWhpeXJMRmdFb2ZDXzZVSkJfaXQxQ3Y5ekNsU0FEZ1p3ZGxJR0k3UHZhbWVXb3h4RFJmbUh4aDZDZllHaHlmemRJTkt5bTItcU11X3NlelhrOGNLR28?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-18T11:39:15+00:00", "published_display": "18 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics(CORT.US) Officer Sells US$3.51 Million in Common Stock", "summary": "Corcept Therapeutics (CORT.US) officer, Gary Charles Robb, sold 100,000 shares of common stock for a total of $3.51 million. The transaction took place on July 16, 2026, and the shares were sold at an average price of $35.1 per share. Following this sale, Robb still directly owns", "url": "https://www.moomoo.com/news/post/73162342/corcept-therapeutics-cortus-officer-sells-us-3-51-million-in", "source_name": "Moomoo", "published_at": "2026-07-18T05:12:00", "published_display": "18 Jul 2026 05:12", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics (CORT) CFO sells 40,000 shares and exercises options", "summary": "Corcept Therapeutics CFO Atabak Mokari exercised options for 40,000 shares and subsequently sold all 40,000 shares on July 15, 2026. The sales were conducted under a Rule 10b5-1 trading plan and involved weighted average prices ranging from $86.7760 to $89.4282 per share. Followi", "url": "https://www.stocktitan.net/sec-filings/CORT/form-4-corcept-therapeutics-inc-insider-trading-activity-27089160b7bc.html", "source_name": "Stock Titan", "published_at": "2026-07-18T04:39:44", "published_display": "18 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics director Wilson sells $882,985 in common stock", "summary": "James N. Wilson, a director at Corcept Therapeutics Inc. (NASDAQ: CORT), sold 10,000 shares of the company's common stock for over $882,985 on July 15, 2026. This transaction was part of a pre-arranged 10b5-1 trading plan. The sale occurs while the stock is near its 52-week high ", "url": "https://www.investing.com/news/insider-trading-news/corcept-therapeutics-director-wilson-sells-882985-in-common-stock-93CH-4799445", "source_name": "Investing.com", "published_at": "2026-07-18T04:39:44", "published_display": "18 Jul 2026 04:39", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics (CORT) director logs 10,000-share indirect sale under 10b5-1 plan", "summary": "Corcept Therapeutics director James N. Wilson, through the James N. Wilson and Pamela D. Wilson Trust, reported an indirect sale of 10,000 shares of common stock on July 15, 2026. The sales were executed under a Rule 10b5-1 trading plan at weighted-average prices ranging from $86", "url": "https://www.stocktitan.net/sec-filings/CORT/form-4-corcept-therapeutics-inc-insider-trading-activity-8deb39ef9e8b.html", "source_name": "Stock Titan", "published_at": "2026-07-18T00:39:44", "published_display": "18 Jul 2026 00:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Corcept Therapeutics (CORT) Stock Analysis: Evaluating the Biotech\u2019s Growth Potential Amidst a Market Cap of $9.86 Billion", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxNUFJBUUJyZk81UkFYdG53QW5BbjVzVGQ0M2QyYVBDbnNWWF9LN1NFOFNxSm9iSzFBU3lZeFhXcmpielBLbzBkM3BFVE5CVFE0ajNXV3YtSURpSURLdktmQVFGTkNkTGF1bjVsUjZURGM1NDU3M1ZrdzktSXZrd0N3T1ozMjI5d184aV9wS3hndGg0akZRSXUzMHFQY1NiWFhDXzNFWWJYaWtCekJ6eXU1WnpuNENBZnpHSldoUFNSd0gxTkYzZGhMNFFYbjdrUHl3WmstX25mUFhTNzR1MDFKWHREdUJGZTZXZ2dlcV9CN1dPTUNwdHFEM19sNVg?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:22:01+00:00", "published_display": "13 Jul 2026 09:22", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook", "summary": "", "url": "https://finance.yahoo.com/m/206100ec-7ffe-3c57-a258-da4c8595f451/corcept-insider-sells-shares.html", "source_name": "Motley Fool", "published_at": "2026-07-12T19:26:35+00:00", "published_display": "12 Jul 2026 19:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics: Recent Relacorilant Rejection Aside, A Good News Story For Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQT0Jjd29aWXE2NFViZmRidlByMFQ2SXdDaFNkeGl0N2pOOGFGRURIMW1IRUZ4V0hUYWo1b3NwUVc1NUZZTkl2WlBBM2FiLWZEMzhOeXBTWTdqRkRaYVAxenVDWjFkVmx0QXRVX0U1UmlMdEJTT0tPTUFxdFhwSUdhSUs1SnY4cDQ5Y0lsR3ZzallhMTZNY0FTTEJaTFpvdl9US3BZdFhxVGFIQVgxZUdNTGlhN05FWTlSV2dJLUduTjdtUzlCV2RVYQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics : CORT", "summary": "This article provides an overview of Corcept Therapeutics (CORT), a biopharmaceutical company focused on treating severe disorders, including Cushing's syndrome with its flagship product Korlym. It highlights the company's robust pipeline, currently in late-stage clinical trials ", "url": "https://247wallst.com/companies/cort/", "source_name": "24/7 Wall St.", "published_at": "2026-07-09T17:40:43", "published_display": "09 Jul 2026 17:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Corcept Therapeutics (CORT) Fully Valued On Its Russell Index Removal?", "summary": "Corcept Therapeutics (CORT) was removed from the Russell 1000 Growth Defensive Index and the Russell 1000 Defensive Index, which primarily impacts trading activity and liquidity. The stock has seen significant share price momentum over the past year, with a 31.1% one-year total s", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/is-corcept-therapeutics-cort-fully-valued-on-its-russell-ind", "source_name": "Simply Wall Street", "published_at": "2026-07-09T13:40:43", "published_display": "09 Jul 2026 13:40", "sentiment": "negative", "sentiment_pct": 41, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept (NASDAQ: CORT) CBO reports 600-share stock gift and holdings", "summary": "Corcept Therapeutics' Chief Business Officer, Gary Charles Robb, reported a gift of 600 shares of common stock on May 27, 2026, with no sale price. Following this transaction, Robb directly holds 25,081 shares, and indirectly holds 49,716 shares through a revocable trust and 12,5", "url": "https://www.stocktitan.net/sec-filings/CORT/form-4-corcept-therapeutics-inc-insider-trading-activity-985de81c25cb.html", "source_name": "Stock Titan", "published_at": "2026-07-09T00:44:49", "published_display": "09 Jul 2026 00:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Corcept Therapeutics Incorporated For: 8 July By Investing.com", "summary": "This article from Investing.com announces a Form 4 filing for Corcept Therapeutics Incorporated (CORT) on July 8. The brief update provides the stock symbol and its recent performance (-1.17%), indicating a transactional report relevant to the company. The rest of the content inc", "url": "https://za.investing.com/news/stock-market-news/form-4-corcept-therapeutics-incorporated-for-8-july-93CH-4361514", "source_name": "Investing.com South Africa", "published_at": "2026-07-08T23:41:49", "published_display": "08 Jul 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider at Corcept (NASDAQ: CORT) sells shares after option exercise", "summary": "Corcept Therapeutics Chief Development Officer William Guyer exercised stock options for 20,000 shares at $21.65 and simultaneously sold them on the open market at weighted average prices of $93.11 and $93.54. These transactions, totaling $1.86 million, were conducted under a pre", "url": "https://www.stocktitan.net/sec-filings/CORT/form-4-corcept-therapeutics-inc-insider-trading-activity-a0ea7c85ce9b.html", "source_name": "Stock Titan", "published_at": "2026-07-08T23:41:49", "published_display": "08 Jul 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics CDO William Guyer sells $1.86m in stock By Investing.com", "summary": "Corcept Therapeutics' Chief Development Officer, William Guyer, sold 20,000 shares of company stock for approximately $1.86 million, executed under a pre-arranged trading plan. This sale occurred near the stock's 52-week high, with the company also having other recent development", "url": "https://ca.investing.com/news/stock-market-news/corcept-therapeutics-cdo-william-guyer-sells-186m-in-stock-93CH-4726264", "source_name": "Investing.com Canada", "published_at": "2026-07-08T23:41:49", "published_display": "08 Jul 2026 23:41", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 CORCEPT THERAPEUTICS INC For: 7 July By Investing.com", "summary": "This article from Investing.com reports on a Form 144 filing for Corcept Therapeutics Inc. (CORT) specifically for July 7th. The article provides the company's stock symbol and a slight negative price change for the day mentioned, indicating a transaction filing relevant to insid", "url": "https://ng.investing.com/news/stock-market-news/form-144-corcept-therapeutics-inc-for-7-july-93CH-2589469", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T13:40:43", "published_display": "08 Jul 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "William Guyer to sell 20,000 CORT shares (NASDAQ: CORT) via option exercise", "summary": "William Guyer has filed a Form 144 to sell 20,000 shares of Corcept Therapeutics Inc. (NASDAQ: CORT) common stock through a stock option exercise on July 7, 2026. The filing also disclosed three previous sales of 20,000 shares each in April, May, and June of 2026, with proceeds r", "url": "https://www.stocktitan.net/sec-filings/CORT/144-corcept-therapeutics-inc-sec-filing-145be5a47f35.html", "source_name": "Stock Titan", "published_at": "2026-07-07T15:40:05", "published_display": "07 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics highlights its endocrine focus as investors watch CORT stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQVlRNaEhLbEJ5STFYZUlkd0U1blhXZnlYZndCcUJtekNidndGcE54Um5vVDZoZUQtV0l5R0JlVDBiT1ZoR2hyMjlzWjllWkV0UDlaWmRjYTc5RW1BM25qMS1PZGpCN0FPdG1oM3JMUFpXc19nbkNlOGk5WTJUS1YzRUpBd3ZlTU9mUVJsUUMycHhydTcxbUZFVGg2dERKd0w1amVlUmFiVkhleHI2dWRSdy05dFN2eWNNNndNc3A0OHlwbVFUaUhodg?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-07T11:31:50+00:00", "published_display": "07 Jul 2026 11:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept (CORT) executive sells 25K shares after exercising options", "summary": "Corcept Therapeutics executive Sean Maduck exercised options for 25,000 shares at $8.27 each and subsequently sold all 25,000 shares in open-market transactions at an average price between $87 and $89 per share. These transactions were made under a Rule 10b5-1 trading plan establ", "url": "https://www.stocktitan.net/sec-filings/CORT/form-4-corcept-therapeutics-inc-insider-trading-activity-16327b858337.html", "source_name": "Stock Titan", "published_at": "2026-07-06T21:10:18", "published_display": "06 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics stock hits 52-week high at 91.1 USD", "summary": "Corcept Therapeutics (CORT) stock recently hit a new 52-week high of $91.10, marking significant appreciation over the past year and year-to-date. This surge has increased the company's market capitalization to $9.68 billion, although InvestingPro analysis suggests the stock is c", "url": "https://www.investing.com/news/company-news/corcept-therapeutics-stock-hits-52week-high-at-911-usd-93CH-4776769", "source_name": "Investing.com", "published_at": "2026-07-06T14:10:19", "published_display": "06 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Corcept\u2019s Exit From Russell Defensive Indexes Reframe Its Risk Profile And Investor Base (CORT)?", "summary": "Corcept Therapeutics (CORT) was removed from the Russell 1000 Defensive and Growth-Defensive Indexes in late June 2026, which may influence index-tracking investors and shift demand for its stock. This move highlights how sentiment and ownership patterns can change as Corcept pur", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/does-corcepts-exit-from-russell-defensive-indexes-reframe-it/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-06T01:10:19", "published_display": "06 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CORT - Corcept Therapeutics Inc Options", "summary": "This article provides a detailed financial overview of Corcept Therapeutics Inc. (CORT), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as EPS, sales growth, insider and institution", "url": "https://finviz.com/stock?t=CORT&p=d&r=y1&ty=oc&ov=chain_date&e=2027-02-19", "source_name": "Finviz", "published_at": "2026-07-04T19:11:09", "published_display": "04 Jul 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Corcept Therapeutics Inc (CORT)", "summary": "This article analyzes the historical performance of an investment in Corcept Therapeutics Inc (CORT). It details how a $1,000 investment would have grown over 1, 5, and 10 years, showcasing significant returns. The article also provides a comprehensive overview of Corcept Therape", "url": "https://www.stocktitan.net/tools/stock-return-calculator/CORT", "source_name": "Stock Titan", "published_at": "2026-07-04T05:09:15", "published_display": "04 Jul 2026 05:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Corcept Therapeutics (CORT) Undervalued On Its Russell Index Removal?", "summary": "Corcept Therapeutics (CORT) was removed from the Russell 1000 Defensive and Growth-Defensive Indices, prompting questions about its valuation despite strong recent share price momentum. While a prominent narrative suggests the stock is 1% overvalued at $88 due to expected revenue", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/is-corcept-therapeutics-cort-undervalued-on-its-russell-inde", "source_name": "Simply Wall Street", "published_at": "2026-07-02T16:10:48", "published_display": "02 Jul 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CORT - Corcept Therapeutics Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Corcept Therapeutics Inc (CORT), including its volatility, key financial ratios, performance metrics, and insider/institutional ownership data. It presents a snapshot of the company's market cap, earnings per share, sales gro", "url": "https://finviz.com/stock?t=CORT&ta=1&p=d&ty=ocv&b=2&ov=chain_strike&s=75", "source_name": "Finviz", "published_at": "2026-07-02T02:10:48", "published_display": "02 Jul 2026 02:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Corcept Therapeutics Incorporated \u2013 NASDAQ:CORT", "summary": "This article provides the forward price-to-sales ratio for Corcept Therapeutics Incorporated (NASDAQ: CORT). It primarily consists of metadata and navigation elements from the TradingView platform, where this financial data point is located. The core content is the mention of the", "url": "https://www.tradingview.com/symbols/NASDAQ-CORT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T01:40:00", "published_display": "01 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Corcept Therapeutics Incorporated \u2013 NASDAQ:CORT", "summary": "This article focuses on the enterprise value to revenue forward for Corcept Therapeutics Incorporated (NASDAQ: CORT). It presents financial data for the company within the context of the pharmaceuticals industry on TradingView. The page provides a snapshot of CORT's financials an", "url": "https://www.tradingview.com/symbols/NASDAQ-CORT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T17:39:14", "published_display": "30 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept sinks after FDA rejects drug to treat hypertension", "summary": "The article states that Corcept's stock sank after the FDA rejected its drug for hypertension, which was a significant setback for the company. There is no further content provided to elaborate on the details of the rejection or its potential impact.", "url": "http://www.msn.com/en-us/health/other/corcept-sinks-after-fda-rejects-drug-to-treat-hypertension/ar-AA1TlLlI?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-30T03:10:15", "published_display": "30 Jun 2026 03:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics Incorporated(NasdaqCM:CORT) dropped from Russell 1000 Defensive Index", "summary": "Corcept Therapeutics Incorporated (NasdaqCM:CORT) has been removed from the Russell 1000 Defensive Index. This news follows a series of recent announcements for the company, including the resubmission of its NDA for a Cushing Syndrome treatment and several insider share sales. De", "url": "https://www.marketscreener.com/news/corcept-therapeutics-incorporated-nasdaqcm-cort-dropped-from-russell-1000-defensive-index-ce7f5fdfda88f12d", "source_name": "marketscreener.com", "published_at": "2026-06-29T18:10:20", "published_display": "29 Jun 2026 18:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept gives FDA new relacorilant data in resubmitted application", "summary": "Corcept Therapeutics has resubmitted its application to the FDA for relacorilant, a treatment for endogenous Cushing's syndrome, including new data analyses requested by the agency. The resubmission provides additional evidence from Phase 3 trials (GRACE and GRADIENT) demonstrati", "url": "https://cushingsdiseasenews.com/news/corcept-gives-fda-new-relacorilant-data-resubmitted-application/", "source_name": "Cushing's Disease News", "published_at": "2026-06-26T16:11:41", "published_display": "26 Jun 2026 16:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics (CORT) Stock After 114% YTD Surge Is The Rally Justified", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics Stock Surges 32%, With A 11-Day Winning Spree", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNNEoycXhuMVJBZDdzMGxtcTh5dXB1MzNhemxOQnA3dEhaZnVvSXkxaWtleE84UXp6aWpUSFptRmFOTWNxRUpKdm9wWXdBWG14OVYwZDJKd2tCVHN1bGQ3U2o4QmpLNzhsOF9uQ05sY19GaHJkcGxsdVVRaU8xNW9GTjN5YTRYSTFEZjZmUm9KNGNISXNhanlqYUhKS3VRWHozZDVBYlZyUVhtNGtHY3I0VHNiNk81MkkyeFFsTHpuTVFXQnc?oc=5", "source_name": "Trefis", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Corcept\u2019s ALS Survival Signal Reframes Cortisol Modulation And Growth Outlook", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Corcept brings new ovarian cancer survival subgroup data to ASCO", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPbDVsWGljZC1mb21XZkRLdkd4VWl4VnN1YlRMa0J2aUxSS3VVZE1hTU1GcFp5Q0hXRUZ5ZzJVYjFFQ3NfcUlqb2pNWHhRVlAtbFpfamVOcEstV2JhVHRNd2U5N0VVUWRqM0ZzTUVTay1zaVhOVjJ2RmNnNkhpSWdYdFdNZTZ1aWh0U08wdXc3MWZwbHBlWXFRaWE2YnREV1B3MTYxelNZaVM1SWlSbG83aUdIcWZmUHZDZ202Rg?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "How The Corcept Therapeutics (CORT) Investment Story Is Shifting After Legal And Regulatory Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNT1dNRGxRYm9WdVFCSEFCUkZtZmJTREM4VUZsWDJSWkVWQTlVaE9DdFlDSEdEMVIzSjlLOVgyX1NGZ3JpVmpDZGl4Y2otZW84MlFoS2NGdW80RDBEaGIzT3MzUkZpQVM5VXVzVTlzMm00ZXVBazMzSUJ1TFdyWjFGZUNLLW9zMm5weWttV2t4WmttYjZrcXNPUnEwa1NZc2FIUlZER1NoVjE3REk?oc=5", "source_name": "Market source", "published_at": "2026-04-11T07:00:00+00:00", "published_display": "11 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics Incorporated Securities Fraud Class", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AJBVV95cUxPLV9qMjktZU1wTENRNVJfdmRlellNTXp3VnNGeXhyMWdHZzVfcl9vNVZJdlJIU281ZkthWXpGMGxZa2ZjV1liX3l4dmJWbF8zWEZNMGR0dndHUlpzaDdGdHl6Y3BrcENPTjY2VnVQUzJ6QUhrM0VzLUZOdFpXTTZtMDNIdmlVeDJxeFVrX1dFelJYaVVLQjdzSE5HZjVyRG83eUwtOFUxY2x5UFVDRGdMU2tza0w1d3BHcUdWZzJYOFN6b0o1X2thUWNpTEZXTWh6SW5VTkc3dmYtR2hvNW1zaEF4bUhJUVpoektSQ2E4WjRVSHJlZUhyTXpqUEl3bUo2LXRtTkhVYVdtLVU5X3JSdU9ycGF4Nzl4UDNuSE9QQi15c1NXNTBIeElVbHoydHB0TkFNdi0zUFZkU3Q0QmtxYUVKb19SRFR0eVB4T3BJWHBPcmZQQnFFRko4MjB4NVk3cEl5ZERPakw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Corcept Therapeutics (CORT) Pricing Make Sense After Recent Share Price Volatility?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPMW8wRW5POEdjX1I5S09tUy1saWVtejN5RThpcjdNWGdHVTRETnlBTmw5RkszM2VEMVFyZ19KYzFRakNjY2M1cUpNZGxiNFlZWXFfTXFfbzlOdU1mejV2anVGYm83Y1pUSFpiYWt3aDhpY1htNGJKSjJ6UXlGVWJHYlF0S0tEUnJQZmxEQTJmZ1c1TFFrX1F0enBqN0lDOFhiQVRlcnBsSQ?oc=5", "source_name": "Market source", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "US Stocks: Corcept Therapeutics shares surge 32% as lead drug gets FDA nod for ovarian cancer", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Economic Times", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics (CORT) Margin Compression Reinforces Bearish Narrative Despite FY 2025 Revenue Strength", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics (CORT) Stock Declines After Court Ruling", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQUHk3bGR6dXAwRXBhMzhKTkhhWndRUl94TG5MbUVqTGxEck9zNjE3U3djb25qRFVDZG8xNUlEQVJfclNYOUxUcWE4UWtTbnBlV0FEV1U1ejRBYmoyRm9CaUxlZVpLa2lFb3hsMVN2RUZCZDNNb2s1dm56bHBXeUIzOGVWaW14dEcwdUliM0xka3FOb092X0tHTEo2WDRiYVU?oc=5", "source_name": "GuruFocus", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics stock falls after losing key patent case appeal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOc19LVkEySDkxQ0VvcEdmX3pWSEJ1MUk4RU1OU1RZUlFZYnBad3ZTZWt0VUxBX180dlBBU1d3UW9kejk4RmFfdU9VWVRhWEJ2czdrTWowV0habmpzUTQyek5GanIwTElsLTlvNGc4Zld5X2FYWUEyNmdtTkFkMm1aMldUVnA0S1VhLTJGNllsUzRKanRXdVR5X0lIbmZUMU1JV2RtakxxakUxXzhLS2pkaGRld0dURHFaaW0tUWxETUI1TDB0cjM3eEpB?oc=5", "source_name": "Investing.com", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Insider Transaction Explained After Shares Tumble 50% in One Day", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNTV80cG1qUDk3ZGQxX0hfTEFuZ3p1d2k2X3NGLWNJUGJHYjdNSThTXy1QYkU3aWRoQVBqbFpWZldRb3lMeG52QjNFdU1vVmxpTzhCVmY1S3ZIYUMwSGZnMUJTV0NldEtQbEhYZFdBWUExWFduRUduNFJxcEFsV0gyQ2llT2tyb0lfRVR2ZXd6RndFWXRmZUVuNlhua0gtZ25uWEI2QUxhYVlkSnZTSlR0MExRY1FBX0RWZE5PdDNR?oc=5", "source_name": "The Motley Fool", "published_at": "2026-01-11T08:00:00+00:00", "published_display": "11 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Price Is Right For Corcept Therapeutics Incorporated (NASDAQ:CORT) Even After Diving 56%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-01T08:00:00+00:00", "published_display": "01 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Corcept (CORT) Stock Is Trading Lower Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxOeTQ2Qk8zcGhPVVR5ck9DOHdqdy02UVFuSW5mNG5Pb2ZWbzFLU2w1anRoNE5sbThGLWVUUXRFZDdrOHJQNUkwOGJOR25pQlJRNVduSFdXMVJ2dVpQb1lmQTNDNHdLUEhQMjM0UFVKczNiM0FIRDRsMVM3N1BkOG5BOTRR?oc=5", "source_name": "Market source", "published_at": "2025-12-23T08:00:00+00:00", "published_display": "23 Dec 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Corcept Sets July 29 Results Call for 5 p.m. Eastern", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPLXowYnNpR3JoZVZnVEk3SWJwYU8tV1E0bS1ZTU15bUo0RkplakhBYUtSbTczc3c5enF6V1NXWWhlMklqajhfNjB6VmNiRmd6cnBDLWVQUkVsb2d6SWFPQjY1UWV0dkQ2dDRORFo3NDFVZkpqbUd3dzhrd2k0TmZRb1MxbE1Jc1hLZUdpU18xNU1uQ0lRQjdUU0Qya1d1bFFjWDdGQUQtSzJjdzBEZG9ydlkwV0lNdmdJRExHNQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-22T20:11:59+00:00", "published_display": "22 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/corcept-therapeutics-announce-second-quarter-200500598.html", "source_name": "Business Wire", "published_at": "2026-07-22T20:05:00+00:00", "published_display": "22 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics stock hits 52-week high at 95.18 USD By Investing.com", "summary": "Corcept Therapeutics (CORT) stock has climbed to a new 52-week high of $95.18, showcasing a 152% return over the past six months and a 163% year-to-date gain, reflecting strong investor confidence and strategic advancements. Despite an InvestingPro analysis indicating the stock m", "url": "https://ca.investing.com/news/stock-market-news/corcept-therapeutics-stock-hits-52week-high-at-9518-usd-93CH-4744412", "source_name": "Investing.com Canada", "published_at": "2026-07-21T14:09:47", "published_display": "21 Jul 2026 14:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% \u2014 Here's What Investors Should Know", "summary": "", "url": "https://finance.yahoo.com/m/735c6d8c-f879-38f7-aea3-94f59ba12108/corcept%27s-cfo-set-his-selling.html", "source_name": "Motley Fool", "published_at": "2026-07-21T00:38:52+00:00", "published_display": "21 Jul 2026 00:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound", "summary": "", "url": "https://finance.yahoo.com/m/b549078f-abaa-3db0-b092-6229b1275909/a-corcept-director-holds-1.5.html", "source_name": "Motley Fool", "published_at": "2026-07-21T00:28:29+00:00", "published_display": "21 Jul 2026 00:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept stock trades near recent highs as Korlym revenue and margins support growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNQ3RCX1Mwelg1alF1OVRwMzBiS2lTeGF0NmRXaTBBY0UwRHVxeDNGTWxXSFNlZHQzTUIzd0FRRGFaS0NYUUU2a2tYSjgyd1VMVWtQSGUtSzdrUHo3Q0NjamdaSXZubDFjMlNJVUxaSUtYSjN3RG9qeTUwM3cyQ2cyVkxCdEZyVWgyVFZUZlZOZ2RNeHB2YmNnbkxPbmxfQ0FObGVvOXhvTjZnYTZYeDdjUjNFajBKSVN4cGt6YzFnNFBNMFM4TkE?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-20T18:09:26+00:00", "published_display": "20 Jul 2026 18:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trump Disclosure Shows Corcept Buy Before FDA Approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQeDdDZU1hLVgyZVUtRjB2OGJuU0JuY2ZtcFpjdDc4X2NhRENqVHJmc0RLSDlrT1Njd3o3VWl6VGp3RHh0amI2X1h3WXNUeWMtSnZwdV9jbWN1b0RzVXpuWUE5cjhMdERzVi1Vc2VhTHp4b1EzYXlBeGhKdXZsYzRJeWcySXZwa3lYckZCZTBjVm8?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-20T17:37:00+00:00", "published_display": "20 Jul 2026 17:37", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics Insider Sold Shares Worth $3,508,277, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/corcept-therapeutics-insider-sold-shares-075204192.html", "source_name": "MT Newswires", "published_at": "2026-07-20T07:52:04+00:00", "published_display": "20 Jul 2026 07:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics (CORT) Stock Could Trade At A Discount As Its 346% Run Looms", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-18T11:39:15+00:00", "published_display": "18 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics(CORT.US) Officer Sells US$3.51 Million in Common Stock", "summary": "Corcept Therapeutics (CORT.US) officer, Gary Charles Robb, sold 100,000 shares of common stock for a total of $3.51 million. The transaction took place on July 16, 2026, and the shares were sold at an average price of $35.1 per share. Following this sale, Robb still directly owns", "url": "https://www.moomoo.com/news/post/73162342/corcept-therapeutics-cortus-officer-sells-us-3-51-million-in", "source_name": "Moomoo", "published_at": "2026-07-18T05:12:00", "published_display": "18 Jul 2026 05:12", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics (CORT) CFO sells 40,000 shares and exercises options", "summary": "Corcept Therapeutics CFO Atabak Mokari exercised options for 40,000 shares and subsequently sold all 40,000 shares on July 15, 2026. The sales were conducted under a Rule 10b5-1 trading plan and involved weighted average prices ranging from $86.7760 to $89.4282 per share. Followi", "url": "https://www.stocktitan.net/sec-filings/CORT/form-4-corcept-therapeutics-inc-insider-trading-activity-27089160b7bc.html", "source_name": "Stock Titan", "published_at": "2026-07-18T04:39:44", "published_display": "18 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics director Wilson sells $882,985 in common stock", "summary": "James N. Wilson, a director at Corcept Therapeutics Inc. (NASDAQ: CORT), sold 10,000 shares of the company's common stock for over $882,985 on July 15, 2026. This transaction was part of a pre-arranged 10b5-1 trading plan. The sale occurs while the stock is near its 52-week high ", "url": "https://www.investing.com/news/insider-trading-news/corcept-therapeutics-director-wilson-sells-882985-in-common-stock-93CH-4799445", "source_name": "Investing.com", "published_at": "2026-07-18T04:39:44", "published_display": "18 Jul 2026 04:39", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics (CORT) director logs 10,000-share indirect sale under 10b5-1 plan", "summary": "Corcept Therapeutics director James N. Wilson, through the James N. Wilson and Pamela D. Wilson Trust, reported an indirect sale of 10,000 shares of common stock on July 15, 2026. The sales were executed under a Rule 10b5-1 trading plan at weighted-average prices ranging from $86", "url": "https://www.stocktitan.net/sec-filings/CORT/form-4-corcept-therapeutics-inc-insider-trading-activity-8deb39ef9e8b.html", "source_name": "Stock Titan", "published_at": "2026-07-18T00:39:44", "published_display": "18 Jul 2026 00:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics (CORT) Stock Analysis: Evaluating the Biotech\u2019s Growth Potential Amidst a Market Cap of $9.86 Billion", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxNUFJBUUJyZk81UkFYdG53QW5BbjVzVGQ0M2QyYVBDbnNWWF9LN1NFOFNxSm9iSzFBU3lZeFhXcmpielBLbzBkM3BFVE5CVFE0ajNXV3YtSURpSURLdktmQVFGTkNkTGF1bjVsUjZURGM1NDU3M1ZrdzktSXZrd0N3T1ozMjI5d184aV9wS3hndGg0akZRSXUzMHFQY1NiWFhDXzNFWWJYaWtCekJ6eXU1WnpuNENBZnpHSldoUFNSd0gxTkYzZGhMNFFYbjdrUHl3WmstX25mUFhTNzR1MDFKWHREdUJGZTZXZ2dlcV9CN1dPTUNwdHFEM19sNVg?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:22:01+00:00", "published_display": "13 Jul 2026 09:22", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook", "summary": "", "url": "https://finance.yahoo.com/m/206100ec-7ffe-3c57-a258-da4c8595f451/corcept-insider-sells-shares.html", "source_name": "Motley Fool", "published_at": "2026-07-12T19:26:35+00:00", "published_display": "12 Jul 2026 19:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics: Recent Relacorilant Rejection Aside, A Good News Story For Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQT0Jjd29aWXE2NFViZmRidlByMFQ2SXdDaFNkeGl0N2pOOGFGRURIMW1IRUZ4V0hUYWo1b3NwUVc1NUZZTkl2WlBBM2FiLWZEMzhOeXBTWTdqRkRaYVAxenVDWjFkVmx0QXRVX0U1UmlMdEJTT0tPTUFxdFhwSUdhSUs1SnY4cDQ5Y0lsR3ZzallhMTZNY0FTTEJaTFpvdl9US3BZdFhxVGFIQVgxZUdNTGlhN05FWTlSV2dJLUduTjdtUzlCV2RVYQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics : CORT", "summary": "This article provides an overview of Corcept Therapeutics (CORT), a biopharmaceutical company focused on treating severe disorders, including Cushing's syndrome with its flagship product Korlym. It highlights the company's robust pipeline, currently in late-stage clinical trials ", "url": "https://247wallst.com/companies/cort/", "source_name": "24/7 Wall St.", "published_at": "2026-07-09T17:40:43", "published_display": "09 Jul 2026 17:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Corcept Therapeutics (CORT) Fully Valued On Its Russell Index Removal?", "summary": "Corcept Therapeutics (CORT) was removed from the Russell 1000 Growth Defensive Index and the Russell 1000 Defensive Index, which primarily impacts trading activity and liquidity. The stock has seen significant share price momentum over the past year, with a 31.1% one-year total s", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/is-corcept-therapeutics-cort-fully-valued-on-its-russell-ind", "source_name": "Simply Wall Street", "published_at": "2026-07-09T13:40:43", "published_display": "09 Jul 2026 13:40", "sentiment": "negative", "sentiment_pct": 41, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept (NASDAQ: CORT) CBO reports 600-share stock gift and holdings", "summary": "Corcept Therapeutics' Chief Business Officer, Gary Charles Robb, reported a gift of 600 shares of common stock on May 27, 2026, with no sale price. Following this transaction, Robb directly holds 25,081 shares, and indirectly holds 49,716 shares through a revocable trust and 12,5", "url": "https://www.stocktitan.net/sec-filings/CORT/form-4-corcept-therapeutics-inc-insider-trading-activity-985de81c25cb.html", "source_name": "Stock Titan", "published_at": "2026-07-09T00:44:49", "published_display": "09 Jul 2026 00:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Corcept Therapeutics Incorporated For: 8 July By Investing.com", "summary": "This article from Investing.com announces a Form 4 filing for Corcept Therapeutics Incorporated (CORT) on July 8. The brief update provides the stock symbol and its recent performance (-1.17%), indicating a transactional report relevant to the company. The rest of the content inc", "url": "https://za.investing.com/news/stock-market-news/form-4-corcept-therapeutics-incorporated-for-8-july-93CH-4361514", "source_name": "Investing.com South Africa", "published_at": "2026-07-08T23:41:49", "published_display": "08 Jul 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider at Corcept (NASDAQ: CORT) sells shares after option exercise", "summary": "Corcept Therapeutics Chief Development Officer William Guyer exercised stock options for 20,000 shares at $21.65 and simultaneously sold them on the open market at weighted average prices of $93.11 and $93.54. These transactions, totaling $1.86 million, were conducted under a pre", "url": "https://www.stocktitan.net/sec-filings/CORT/form-4-corcept-therapeutics-inc-insider-trading-activity-a0ea7c85ce9b.html", "source_name": "Stock Titan", "published_at": "2026-07-08T23:41:49", "published_display": "08 Jul 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics CDO William Guyer sells $1.86m in stock By Investing.com", "summary": "Corcept Therapeutics' Chief Development Officer, William Guyer, sold 20,000 shares of company stock for approximately $1.86 million, executed under a pre-arranged trading plan. This sale occurred near the stock's 52-week high, with the company also having other recent development", "url": "https://ca.investing.com/news/stock-market-news/corcept-therapeutics-cdo-william-guyer-sells-186m-in-stock-93CH-4726264", "source_name": "Investing.com Canada", "published_at": "2026-07-08T23:41:49", "published_display": "08 Jul 2026 23:41", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 CORCEPT THERAPEUTICS INC For: 7 July By Investing.com", "summary": "This article from Investing.com reports on a Form 144 filing for Corcept Therapeutics Inc. (CORT) specifically for July 7th. The article provides the company's stock symbol and a slight negative price change for the day mentioned, indicating a transaction filing relevant to insid", "url": "https://ng.investing.com/news/stock-market-news/form-144-corcept-therapeutics-inc-for-7-july-93CH-2589469", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T13:40:43", "published_display": "08 Jul 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "William Guyer to sell 20,000 CORT shares (NASDAQ: CORT) via option exercise", "summary": "William Guyer has filed a Form 144 to sell 20,000 shares of Corcept Therapeutics Inc. (NASDAQ: CORT) common stock through a stock option exercise on July 7, 2026. The filing also disclosed three previous sales of 20,000 shares each in April, May, and June of 2026, with proceeds r", "url": "https://www.stocktitan.net/sec-filings/CORT/144-corcept-therapeutics-inc-sec-filing-145be5a47f35.html", "source_name": "Stock Titan", "published_at": "2026-07-07T15:40:05", "published_display": "07 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics highlights its endocrine focus as investors watch CORT stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQVlRNaEhLbEJ5STFYZUlkd0U1blhXZnlYZndCcUJtekNidndGcE54Um5vVDZoZUQtV0l5R0JlVDBiT1ZoR2hyMjlzWjllWkV0UDlaWmRjYTc5RW1BM25qMS1PZGpCN0FPdG1oM3JMUFpXc19nbkNlOGk5WTJUS1YzRUpBd3ZlTU9mUVJsUUMycHhydTcxbUZFVGg2dERKd0w1amVlUmFiVkhleHI2dWRSdy05dFN2eWNNNndNc3A0OHlwbVFUaUhodg?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-07T11:31:50+00:00", "published_display": "07 Jul 2026 11:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept (CORT) executive sells 25K shares after exercising options", "summary": "Corcept Therapeutics executive Sean Maduck exercised options for 25,000 shares at $8.27 each and subsequently sold all 25,000 shares in open-market transactions at an average price between $87 and $89 per share. These transactions were made under a Rule 10b5-1 trading plan establ", "url": "https://www.stocktitan.net/sec-filings/CORT/form-4-corcept-therapeutics-inc-insider-trading-activity-16327b858337.html", "source_name": "Stock Titan", "published_at": "2026-07-06T21:10:18", "published_display": "06 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics stock hits 52-week high at 91.1 USD", "summary": "Corcept Therapeutics (CORT) stock recently hit a new 52-week high of $91.10, marking significant appreciation over the past year and year-to-date. This surge has increased the company's market capitalization to $9.68 billion, although InvestingPro analysis suggests the stock is c", "url": "https://www.investing.com/news/company-news/corcept-therapeutics-stock-hits-52week-high-at-911-usd-93CH-4776769", "source_name": "Investing.com", "published_at": "2026-07-06T14:10:19", "published_display": "06 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Corcept\u2019s Exit From Russell Defensive Indexes Reframe Its Risk Profile And Investor Base (CORT)?", "summary": "Corcept Therapeutics (CORT) was removed from the Russell 1000 Defensive and Growth-Defensive Indexes in late June 2026, which may influence index-tracking investors and shift demand for its stock. This move highlights how sentiment and ownership patterns can change as Corcept pur", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/does-corcepts-exit-from-russell-defensive-indexes-reframe-it/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-06T01:10:19", "published_display": "06 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CORT - Corcept Therapeutics Inc Options", "summary": "This article provides a detailed financial overview of Corcept Therapeutics Inc. (CORT), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as EPS, sales growth, insider and institution", "url": "https://finviz.com/stock?t=CORT&p=d&r=y1&ty=oc&ov=chain_date&e=2027-02-19", "source_name": "Finviz", "published_at": "2026-07-04T19:11:09", "published_display": "04 Jul 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Corcept Therapeutics Inc (CORT)", "summary": "This article analyzes the historical performance of an investment in Corcept Therapeutics Inc (CORT). It details how a $1,000 investment would have grown over 1, 5, and 10 years, showcasing significant returns. The article also provides a comprehensive overview of Corcept Therape", "url": "https://www.stocktitan.net/tools/stock-return-calculator/CORT", "source_name": "Stock Titan", "published_at": "2026-07-04T05:09:15", "published_display": "04 Jul 2026 05:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Corcept Therapeutics (CORT) Undervalued On Its Russell Index Removal?", "summary": "Corcept Therapeutics (CORT) was removed from the Russell 1000 Defensive and Growth-Defensive Indices, prompting questions about its valuation despite strong recent share price momentum. While a prominent narrative suggests the stock is 1% overvalued at $88 due to expected revenue", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/is-corcept-therapeutics-cort-undervalued-on-its-russell-inde", "source_name": "Simply Wall Street", "published_at": "2026-07-02T16:10:48", "published_display": "02 Jul 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CORT - Corcept Therapeutics Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Corcept Therapeutics Inc (CORT), including its volatility, key financial ratios, performance metrics, and insider/institutional ownership data. It presents a snapshot of the company's market cap, earnings per share, sales gro", "url": "https://finviz.com/stock?t=CORT&ta=1&p=d&ty=ocv&b=2&ov=chain_strike&s=75", "source_name": "Finviz", "published_at": "2026-07-02T02:10:48", "published_display": "02 Jul 2026 02:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Corcept Therapeutics Incorporated \u2013 NASDAQ:CORT", "summary": "This article provides the forward price-to-sales ratio for Corcept Therapeutics Incorporated (NASDAQ: CORT). It primarily consists of metadata and navigation elements from the TradingView platform, where this financial data point is located. The core content is the mention of the", "url": "https://www.tradingview.com/symbols/NASDAQ-CORT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T01:40:00", "published_display": "01 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Corcept Therapeutics Incorporated \u2013 NASDAQ:CORT", "summary": "This article focuses on the enterprise value to revenue forward for Corcept Therapeutics Incorporated (NASDAQ: CORT). It presents financial data for the company within the context of the pharmaceuticals industry on TradingView. The page provides a snapshot of CORT's financials an", "url": "https://www.tradingview.com/symbols/NASDAQ-CORT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T17:39:14", "published_display": "30 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept sinks after FDA rejects drug to treat hypertension", "summary": "The article states that Corcept's stock sank after the FDA rejected its drug for hypertension, which was a significant setback for the company. There is no further content provided to elaborate on the details of the rejection or its potential impact.", "url": "http://www.msn.com/en-us/health/other/corcept-sinks-after-fda-rejects-drug-to-treat-hypertension/ar-AA1TlLlI?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-30T03:10:15", "published_display": "30 Jun 2026 03:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics Incorporated(NasdaqCM:CORT) dropped from Russell 1000 Defensive Index", "summary": "Corcept Therapeutics Incorporated (NasdaqCM:CORT) has been removed from the Russell 1000 Defensive Index. This news follows a series of recent announcements for the company, including the resubmission of its NDA for a Cushing Syndrome treatment and several insider share sales. De", "url": "https://www.marketscreener.com/news/corcept-therapeutics-incorporated-nasdaqcm-cort-dropped-from-russell-1000-defensive-index-ce7f5fdfda88f12d", "source_name": "marketscreener.com", "published_at": "2026-06-29T18:10:20", "published_display": "29 Jun 2026 18:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept gives FDA new relacorilant data in resubmitted application", "summary": "Corcept Therapeutics has resubmitted its application to the FDA for relacorilant, a treatment for endogenous Cushing's syndrome, including new data analyses requested by the agency. The resubmission provides additional evidence from Phase 3 trials (GRACE and GRADIENT) demonstrati", "url": "https://cushingsdiseasenews.com/news/corcept-gives-fda-new-relacorilant-data-resubmitted-application/", "source_name": "Cushing's Disease News", "published_at": "2026-06-26T16:11:41", "published_display": "26 Jun 2026 16:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics (CORT) Stock After 114% YTD Surge Is The Rally Justified", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics Stock Surges 32%, With A 11-Day Winning Spree", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNNEoycXhuMVJBZDdzMGxtcTh5dXB1MzNhemxOQnA3dEhaZnVvSXkxaWtleE84UXp6aWpUSFptRmFOTWNxRUpKdm9wWXdBWG14OVYwZDJKd2tCVHN1bGQ3U2o4QmpLNzhsOF9uQ05sY19GaHJkcGxsdVVRaU8xNW9GTjN5YTRYSTFEZjZmUm9KNGNISXNhanlqYUhKS3VRWHozZDVBYlZyUVhtNGtHY3I0VHNiNk81MkkyeFFsTHpuTVFXQnc?oc=5", "source_name": "Trefis", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept\u2019s ALS Survival Signal Reframes Cortisol Modulation And Growth Outlook", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept brings new ovarian cancer survival subgroup data to ASCO", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPbDVsWGljZC1mb21XZkRLdkd4VWl4VnN1YlRMa0J2aUxSS3VVZE1hTU1GcFp5Q0hXRUZ5ZzJVYjFFQ3NfcUlqb2pNWHhRVlAtbFpfamVOcEstV2JhVHRNd2U5N0VVUWRqM0ZzTUVTay1zaVhOVjJ2RmNnNkhpSWdYdFdNZTZ1aWh0U08wdXc3MWZwbHBlWXFRaWE2YnREV1B3MTYxelNZaVM1SWlSbG83aUdIcWZmUHZDZ202Rg?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Corcept Therapeutics (CORT) Investment Story Is Shifting After Legal And Regulatory Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNT1dNRGxRYm9WdVFCSEFCUkZtZmJTREM4VUZsWDJSWkVWQTlVaE9DdFlDSEdEMVIzSjlLOVgyX1NGZ3JpVmpDZGl4Y2otZW84MlFoS2NGdW80RDBEaGIzT3MzUkZpQVM5VXVzVTlzMm00ZXVBazMzSUJ1TFdyWjFGZUNLLW9zMm5weWttV2t4WmttYjZrcXNPUnEwa1NZc2FIUlZER1NoVjE3REk?oc=5", "source_name": "Market source", "published_at": "2026-04-11T07:00:00+00:00", "published_display": "11 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics Incorporated Securities Fraud Class", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AJBVV95cUxPLV9qMjktZU1wTENRNVJfdmRlellNTXp3VnNGeXhyMWdHZzVfcl9vNVZJdlJIU281ZkthWXpGMGxZa2ZjV1liX3l4dmJWbF8zWEZNMGR0dndHUlpzaDdGdHl6Y3BrcENPTjY2VnVQUzJ6QUhrM0VzLUZOdFpXTTZtMDNIdmlVeDJxeFVrX1dFelJYaVVLQjdzSE5HZjVyRG83eUwtOFUxY2x5UFVDRGdMU2tza0w1d3BHcUdWZzJYOFN6b0o1X2thUWNpTEZXTWh6SW5VTkc3dmYtR2hvNW1zaEF4bUhJUVpoektSQ2E4WjRVSHJlZUhyTXpqUEl3bUo2LXRtTkhVYVdtLVU5X3JSdU9ycGF4Nzl4UDNuSE9QQi15c1NXNTBIeElVbHoydHB0TkFNdi0zUFZkU3Q0QmtxYUVKb19SRFR0eVB4T3BJWHBPcmZQQnFFRko4MjB4NVk3cEl5ZERPakw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Corcept Therapeutics (CORT) Pricing Make Sense After Recent Share Price Volatility?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPMW8wRW5POEdjX1I5S09tUy1saWVtejN5RThpcjdNWGdHVTRETnlBTmw5RkszM2VEMVFyZ19KYzFRakNjY2M1cUpNZGxiNFlZWXFfTXFfbzlOdU1mejV2anVGYm83Y1pUSFpiYWt3aDhpY1htNGJKSjJ6UXlGVWJHYlF0S0tEUnJQZmxEQTJmZ1c1TFFrX1F0enBqN0lDOFhiQVRlcnBsSQ?oc=5", "source_name": "Market source", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US Stocks: Corcept Therapeutics shares surge 32% as lead drug gets FDA nod for ovarian cancer", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Economic Times", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics (CORT) Margin Compression Reinforces Bearish Narrative Despite FY 2025 Revenue Strength", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxQY1dUZW9icGZwZkFkT3pheDFhbFRfNnY5bWk2SmJ2ZklEVUw4eWIxV3hwWTJ3TUF0SWUycEd0V0lUR09wR0RrWlJHbjkzUWZjcl9ORjBBRkJ3ZFoxX2hGSWhZTUc3OC1Ic3l2UDlsdTgxUXJnWGtFQ0lIZDNMWHV4S1U1SmdjQ0hYSGdmcnZKcGxZbG4tNXEtR2dLeHdqY0MxTVVqUER5YUduT01Bcmx4MEtSUFlpNVUtLVh0QmxVZGh4ZVQzQUNvd3BkZVR0SzFfSzdIWDNTN3Q2eUJHUHEyOXJNcGFBR1o0c3fSAe8BQVVfeXFMTlZxT2Yyc1RwNGZpQWZ3T1k4ZjlmSUhwRTdyRG5PdHBBTXQyd2l5M1l0TnVURlFuenJvYm81UWN4dndBTlFOY0xuMXNCTGtac1pjNE9QUWkxMkRGTlJyMFZrSF81SC1kd3l5NnJOYXlwNUYySkpNS3pXME1USEoxQ1cxdVQySUVybjF4cVNyMlRLd19tY1JnazVxbzdXcU94MnJxXzJRMUI3Y3Z6SmlRcUYwd1JNNFdQM1pxQUxNRlJkczQ0eFNPc1ZRMnIyM3dFQVQ3SXFaSXZ5VkhHTGFiWWhrLV85RTNhUEl3Q1JzcDg?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics (CORT) Stock Declines After Court Ruling", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQUHk3bGR6dXAwRXBhMzhKTkhhWndRUl94TG5MbUVqTGxEck9zNjE3U3djb25qRFVDZG8xNUlEQVJfclNYOUxUcWE4UWtTbnBlV0FEV1U1ejRBYmoyRm9CaUxlZVpLa2lFb3hsMVN2RUZCZDNNb2s1dm56bHBXeUIzOGVWaW14dEcwdUliM0xka3FOb092X0tHTEo2WDRiYVU?oc=5", "source_name": "GuruFocus", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Therapeutics stock falls after losing key patent case appeal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOc19LVkEySDkxQ0VvcEdmX3pWSEJ1MUk4RU1OU1RZUlFZYnBad3ZTZWt0VUxBX180dlBBU1d3UW9kejk4RmFfdU9VWVRhWEJ2czdrTWowV0habmpzUTQyek5GanIwTElsLTlvNGc4Zld5X2FYWUEyNmdtTkFkMm1aMldUVnA0S1VhLTJGNllsUzRKanRXdVR5X0lIbmZUMU1JV2RtakxxakUxXzhLS2pkaGRld0dURHFaaW0tUWxETUI1TDB0cjM3eEpB?oc=5", "source_name": "Investing.com", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Corcept Insider Transaction Explained After Shares Tumble 50% in One Day", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNTV80cG1qUDk3ZGQxX0hfTEFuZ3p1d2k2X3NGLWNJUGJHYjdNSThTXy1QYkU3aWRoQVBqbFpWZldRb3lMeG52QjNFdU1vVmxpTzhCVmY1S3ZIYUMwSGZnMUJTV0NldEtQbEhYZFdBWUExWFduRUduNFJxcEFsV0gyQ2llT2tyb0lfRVR2ZXd6RndFWXRmZUVuNlhua0gtZ25uWEI2QUxhYVlkSnZTSlR0MExRY1FBX0RWZE5PdDNR?oc=5", "source_name": "The Motley Fool", "published_at": "2026-01-11T08:00:00+00:00", "published_display": "11 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Price Is Right For Corcept Therapeutics Incorporated (NASDAQ:CORT) Even After Diving 56%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-01T08:00:00+00:00", "published_display": "01 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Corcept (CORT) Stock Is Trading Lower Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxOeTQ2Qk8zcGhPVVR5ck9DOHdqdy02UVFuSW5mNG5Pb2ZWbzFLU2w1anRoNE5sbThGLWVUUXRFZDdrOHJQNUkwOGJOR25pQlJRNVduSFdXMVJ2dVpQb1lmQTNDNHdLUEhQMjM0UFVKczNiM0FIRDRsMVM3N1BkOG5BOTRR?oc=5", "source_name": "Market source", "published_at": "2025-12-23T08:00:00+00:00", "published_display": "23 Dec 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 107, "total_relevant": 60, "sentiment_summary": {"positive": 14, "negative": 12, "neutral": 34, "score": 51, "total": 60, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 20.5, "count": 36}, {"event": "earnings", "label": "Earnings", "weight": 8.11, "count": 17}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 12}, "market_context": {"has_market_context": true, "latest_close": 90.52, "latest_week": "2026-07-17", "one_week_move": -1.5, "four_week_move": 13.3, "twelve_week_move": 96.5, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.579882, "market_dynamics_buy_signal": false, "relative_strength": 28.18067, "fair_value_gap": 83.3, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 56.4346, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.5% over one week, +13.3% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 60, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 9}, {"label": "Market source", "count": 9}, {"label": "simplywall.st", "count": 7}, {"label": "Motley Fool", "count": 3}, {"label": "Investing.com", "count": 3}, {"label": "Simply Wall Street", "count": 3}, {"label": "TradingView", "count": 3}, {"label": "Investing.com Canada", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 36}, {"label": "Earnings", "count": 17}, {"label": "Regulatory and legal", "count": 3}, {"label": "Guidance", "count": 2}, {"label": "Balance sheet", "count": 1}, {"label": "Macro sensitivity", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-1.5% over one week, +13.3% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Corcept Sets July 29 Results Call for 5 p.m. Eastern"}], "updated_at": "2026-07-23T03:38:42.250235+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}